SynBiotic SE Asset Resilience Ratio
SynBiotic SE asset resilience ratio. SynBiotic SE (SBX) has an Asset Resilience Ratio of 5.09% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SynBiotic SE (SBX) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of SynBiotic SE (2020–2024)
Asset resilience ratio of SynBiotic SE from 2020 to 2024. This chart shows how SynBiotic SE's Asset Resilience Ratio has changed over time. Read SBX total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down SynBiotic SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SBX asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €2.07 Million | 5.09% |
| Total Liquid Assets | €2.07 Million | 5.09% |
Asset Resilience Insights
- Limited Liquidity: SynBiotic SE maintains only 5.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SynBiotic SE Industry Peers by Asset Resilience Ratio
Compare SynBiotic SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
SynBiotic SE Asset Resilience Ratio by Year (2020–2024)
SynBiotic SE asset resilience ratio by year from 2020 to 2024. The table below shows the annual Asset Resilience Ratio data for SynBiotic SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.34% | €1.98 Million ≈ $2.32 Million |
€45.71 Million ≈ $53.44 Million |
-3.41pp |
| 2023-12-31 | 7.75% | €2.71 Million ≈ $3.16 Million |
€34.92 Million ≈ $40.82 Million |
+2.66pp |
| 2022-12-31 | 5.09% | €2.07 Million ≈ $2.42 Million |
€40.62 Million ≈ $47.49 Million |
+1.73pp |
| 2021-12-31 | 3.36% | €2.04 Million ≈ $2.38 Million |
€60.65 Million ≈ $70.90 Million |
+3.21pp |
| 2020-12-31 | 0.15% | €52.14K ≈ $60.95K |
€35.03 Million ≈ $40.95 Million |
-- |
About SynBiotic SE
SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. T… Read more